Recently a phase I clinical trial has been started in Italy to bridge patients with acute liver failure (ALF) to orthotopic liver transplantation (OLT) by the AMC-bioartificial liver (AMC-BAL). The AMC-BAL is charged with 10 × 109 viable primary porcine hepatocytes isolated from a specified pathogen-free (SPF) pig. Here we report a patient with ALF due to acute HBV infection. This patient was treated for 35 h by two AMC-BAL treatments and was bridged to OLT. There was improvement of biochemical and clinical parameters during the treatment. No severe adverse events were observed during treatment and follow-up of 15 months after hospital discharge. Possible porcine endogenous retrovirus (PERV) activity could not be detected in the patient's blood or blood cells up to 12 months after treatment.
BernuauJ.; BenhamouJ. P.Fulminant and subfulminant liver failure. In: McIntyreN.; BenhamouJ. P.; BircherJ.; RizzettoM.; RodesJ., eds. Oxford textbook of clinical hepatology.Oxford/New York/Tokyo: Oxford University Press;1991: 923–942.
3.
de RaveS.; TilanusH. W.; van der LindenJ.; de ManR. A.; van der BergB.; HopW. C. J.; IjzermansJ. N. M.; ZondervanP. E.; MetselaarH. J.The importance of orthotopic liver transplantation in acute hepatic failure.Transpl. Int.15: 29–33; 2002.
4.
DoniniA.; BaccaraniU.; RisalitiA.; DegrassiA.; BresadolaF.Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device.Am. J. Gastroenterol.95: 1102–1104; 2000.
5.
EllisA. J.; HughesR. D.; WendonJ. A.; DunneJ.; LangleyP. G.; KellyJ. H.; GislasonG. T.; SussmanN. L.; WilliamsR.Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure.Hepatology24: 1446–1451; 1996.
6.
FlendrigL. M.; CaliseF.; Di FlorioE.Significantly improved survival time in pigs with complete liver ischemia treated with a novel bioartificial liver.Int. J. Artif. Organs22: 701–708; 1999.
7.
FlendrigL. M.; ChamuleauR. A.; MaasM. A.; DaalhuisenJ.; HassetB.; KiltyC. G.; DoyleS.; LadigesN. C. J. J.; JorningG. C. A.; la SoeJ. W.; SommeijerD.; te VeldeA. A.Evaluation of a novel bioartificial liver in rats with complete liver ischemia: Treatment efficacy and species-specific α-GST detection to monitor hepatocyte viability.J. Hepatol.30: 311–320; 1999.
8.
FlendrigL. M.; la SoeJ. W.; JorningG. G.; SteenbeekA.; KarlsenO. T.; BovéeW. M. M. J.; LadigesN. C. J. J.; te VeldeA. A.; ChamuleauR. A. F. M.In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates.J. Hepatol.26: 1379–1392; 1997.
9.
HerringC.; CunninghamD. A.; WhittamA. J.; Fernandez-SuarezX. M.; LangfordG. A.Monitoring xenotransplant recipients for infection by PERV.Clin. Biochem.34: 23–27; 2001.
MargulisM. S.; ErukhimovE. A.; AndreimanL. A.Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency.Resuscitation18: 85–94; 1989.
MazariegosG. V.; KramerD. J.; LopezR. C.; ShakilA. O.; RosenbloomA. J.; DeVeraM.; GiraldoM.; GroganT. A.; ZhuY.; FulmerM. L.; AmiotB. P.; PatzerJ. F.II. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients.ASAIO J.47: 471–475; 2001.
16.
MorsianiE.; PazziP.; PuvianiA. C.; BrogliM.; ValieriL.; GoriniP.; ScolettaP.; MarangoniE.; RagazziR.; AzzenaG.; FrazzoliE.; Di LucaD.; CassaiE.; LombardiG.; CavallariA.; FaenzaS.; PasettoA.; Girardisk M.; JovineE.; PinnaA. D.Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients.Int. J. Artif. Organs25: 192–202; 2002.
17.
MundtA.; PuhlG.; MullerA.; SauerI. M.; MullerC.; RichardR.; FotopoulouC.; DollR.; GabeleinG.; HohnW.; HofbauerR.; NeuhausP.; GerlachJ. C.A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver support.Int. J. Artif. Organs25: 542–548; 2002.
18.
PatienceC.; TakeuchiY.; WeisR. A.Infection of human cells by an endogenous retrovirus of pigs.Nat. Med.3: 282–286; 1997.
19.
ParadisK.; LangfordG.; LongZ.; HeneineW.; SandstromP.; SwitzerW. M.; ChapmanL. E.; LockeyC.; OnionsD.; The XEN 111 Study Group; OttoE.Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue.Science285: 1236–1241; 1999.
20.
SosefM. N.; AbrahamseL. S.; van de KerkhoveM. P.; HartmanR.; ChamuleauR. A.; van GulikT. M.Assessment of the AMC-bioartificial liver in the anhepatic pig.Transplantation73: 204–209; 2002.
21.
te VeldeA. A.; LadigesN. C.; FlendrigL. M.; ChamuleauR. A.Functional activity of isolated pig hepatocytes attached to different extracellular matrix substrates. Implication for application of pig hepatocytes in a bioartificial liver.J. Hepatol.23: 184–192; 1995.
22.
United Network for Organ Sharing.Liver Transplantation data2002; www.unos.org.
23.
van der LaanL. J.; LockeyC.; GriffethB. C.Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice.Nature407: 90–94; 2000.
24.
XueY. L.; ZhaoS. F.; LuoY.; LiX. J.; DuanZ. P.; ChenX. P.; LiW. G.; HuangX. Q.; LiY. L.; CuiX.; ZhongD. G.; ZhangZ. Y.; HuangZ. Q.TECA hybrid artificial liver support system in treatment of acute liver failure.World J. Gastroenterol.7: 826–829; 2001.
